Analysts Expect Redhill Biopharma Ltd. (RDHL) to Post -$0.58 EPS
Wall Street brokerages expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to post earnings of ($0.58) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Redhill Biopharma’s earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.62). Redhill Biopharma reported earnings per share of ($0.60) during the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is scheduled to report its next earnings report on Tuesday, July 25th.
On average, analysts expect that Redhill Biopharma will report full-year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.04). For the next financial year, analysts forecast that the business will report earnings of ($2.23) per share, with EPS estimates ranging from ($2.40) to ($2.05). Zacks’ EPS calculations are an average based on a survey of analysts that cover Redhill Biopharma.
Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.14.
RDHL has been the subject of a number of research analyst reports. FBR & Co reissued a “buy” rating on shares of Redhill Biopharma in a research report on Wednesday, April 5th. Zacks Investment Research raised shares of Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Tuesday, July 4th. Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th.
A number of institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. raised its position in shares of Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 6,172 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Redhill Biopharma during the first quarter valued at $101,000. Family Management Corp acquired a new position in shares of Redhill Biopharma during the first quarter valued at $163,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Redhill Biopharma during the fourth quarter valued at $266,000. 12.31% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Redhill Biopharma (NASDAQ:RDHL) traded up 3.67% during trading on Wednesday, reaching $8.48. 50,083 shares of the company traded hands. Redhill Biopharma has a 12 month low of $8.20 and a 12 month high of $16.54. The firm has a 50-day moving average price of $9.43 and a 200-day moving average price of $9.89. The firm’s market capitalization is $144.22 million.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.